TCGA-AN-A0AJ-01A-11R-A00Z-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 10
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.620
- G2M_CHECKPOINT+0.570
- MYC_TARGETS_V2+0.550
- MYC_TARGETS_V1+0.530
- ALLOGRAFT_REJECTION+0.450
- MTORC1_SIGNALING+0.390
- INTERFERON_GAMMA_RESPONSE+0.370
- DNA_REPAIR+0.250
- IL6_JAK_STAT3_SIGNALING+0.250
- PI3K_AKT_MTOR_SIGNALING+0.250
Top 10 suppressed
- MYOGENESIS-0.380
- TGF_BETA_SIGNALING-0.360
- NOTCH_SIGNALING-0.320
- APICAL_SURFACE-0.280
- ANGIOGENESIS-0.240
- APICAL_JUNCTION-0.230
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.210
- UV_RESPONSE_DN-0.190
- WNT_BETA_CATENIN_SIGNALING-0.170
- BILE_ACID_METABOLISM-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-C8-A1HM-01A-12R-A137-07 | — | C | 0.882 |
| 2 | SRR8518289 | — | E | 0.875 |
| 3 | SRR35579824 | — | E | 0.874 |
| 4 | SRR1313135 | — | C | 0.871 |
| 5 | TCGA-BH-A209-01A-11R-A157-07 | — | D | 0.870 |
| 6 | TCGA-E2-A14N-01A-31R-A137-07 | — | E | 0.864 |
| 7 | SRR8518156 | — | D | 0.862 |
| 8 | MONOMAC6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.861 |
| 9 | TCGA-A8-A09I-01A-22R-A034-07 | — | C | 0.861 |
| 10 | TCGA-18-3416-01A-01R-0980-07 | — | cohortSQ2 | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.550 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.210 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |